Thursday 16 December, 3pm AEDT
Bioprinting holds extreme promise in many areas of clinical application, especially in areas such as the manufacture of tissue engineered advanced therapy medicinal products (ATMPs). However, for bioprinting to be a commercially acceptable clinical solution, there are a number of hurdles that need to be overcome:
- Standardisation of manufacturing processes
- Improvement of tissue functionality
- Scalability and reproducibility
- Cost effectiveness and profitability
Poietis’ Next-Generation Bioprinting (NGB) biomanufacturing solutions address these problems and offer a seamless route to commercial-scale manufacturing. They achieve this by integrating automation and robotic technologies and is coupled with online sensors – including cell microscopy. In addition, they include all bioprinting techniques (laser-assisted bioprinting, bioextrusion, micro-valve bioprinting) making the platform highly versatile and able, catering to the vast majority of imaginable application. The capabilities, benefits and applications will be discussed in this webinar.
Poieskein, bioprinted skin substitute.
Presenter – Dr. Fabien Guillemot, CEO & Founder, Poietis
Dr. Fabien Guillemot is a scientist-turned-entrepreneur, CEO and Founder of Poietis, whose mission is to develop and market the Next-Gen Bioprinting platform to bring Tissue Engineering therapies to patients. Fabien has an over 20 years experience in the field of Biofabrication. He holds a PhD in Material Science (INSA, 2000) and an Habilitation in Health and Life Sciences (Bordeaux University, 2010). He was appointed Researcher at INSERM, France in 2005, and invited researcher at Harvard University in 2010. Bioprinting pioneer and inventor (with 100+ publications and 13 patents), he left for entrepreneurship via training at HEC-Paris.